ARTICLE | Clinical News
UV-4B: Ph Ib started
February 3, 2017 12:40 AM UTC
Emergent began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate ascending doses of UV-4B oral solution thrice daily for 7 days in about 40 healthy volunteers. The company is develop...
BCIQ Company Profiles
BCIQ Target Profiles